|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.
April 4, 2019 3pm-6:30pmUniv. Shady Grove Convention Center 9630 Gudelsky Drive, Rockville, Maryland 20850
Welcome to the Spring 2019 Meeting of the Metro DC Chapter of the Laboratory Research Interest Group! Although we have deep roots in Laboratory Automation, we also invite you to learn about other research technologies, new tools, and projects that are available and ongoing in the Capitol Bioscience hub!
This years theme is Emerging Technologies at the Forefront of Bioscience, with emphasis on 3D Cell Printing, Organoids, Tissue-On-Chip models, and Artificial Intelligence in Bioscience.
Attendance is free with your Eventbrite reservation, and we encourage you to register early.
– Winner to be announced during 2019 BioHealth Capital Region Forum –
Five innovative companies focused on the diagnosis or treatment of Multiple Sclerosis, TBI, Autism, Spinal misalignment, and Metastatic Cancer will present their innovative technologies to a panel of judges and industry leaders on April 9th during the 2019 BioHealth Capital Region Forum, at the AstraZeneca campus in Gaithersburg, Maryland. Founded by BioHealth Innovation, Inc. (BHI) and AstraZeneca in 2016, the annual Crab Trap Competition highlights biohealth companies with strong commercial potential. The five finalists were selected from a competitive field of almost fifty entries. The 4th Annual Crab Trap Competition is sponsored by Wilson Sonsini Goodrich & Rosati. The grand prize this year is $10,000.
In 2016, the initial prize was awarded to Sonavex, a commercial stage Johns Hopkins spin-out focused on Empowered Patient Care. The company’s first technology is a dual-component system comprising an FDA-cleared bioabsorbable implant (EchoMark) and an FDA-cleared custom automated ultrasound (EchoSure) to detect post-operative vascular complications prior to catastrophic surgical failures that represent a $3B annual market and cost hospitals up to $577,000 per instance. The company closed a $4.5M Series A in 2018, recently secured a $3M NIH grant and is currently raising its Series B. In 2017, the winner was another Johns Hopkins (JH*) spinout, LifeSprout, developer of a suite of products to address soft tissue needs in the aesthetic and reconstructive markets. Last year’s winner, Galen Robotics, is developing, in partnership with JHU, a surgical robot to make minimally invasive surgeries faster, safer and more precise. The company plans a 510k submission next year, is raising Series A financing, and will be relocating the HQ team in CA to join their engineering experts in Baltimore.
The 2019 BioHealth Capital Region Crab Trap Finalists presenting at the forum at 9:30 a.m. on Tuesday, April 9th, are:
BeCareLink – Predictive Artificial Intelligence Digital Therapeutic Mobile Platform for Multiple Sclerosis and other neurological conditions.
BRAINBox Solutions – Multi-Modality capability to diagnose and provide prognostic information for mild Traumatic Brain Injury.
Floreo Inc. – Leveraging the power of virtual reality to develop a subscription platform that delivers immersive, fun, and affordable lessons for children and adults with autism spectrum disorder (ASD).
Spine Align – Spine Align is a medical device company developing technologies that enable spine surgeons to make real-time intraoperative measurements of spinal alignment.
Unleash Immuno Oncolytics – Developing armed, oncolytic viruses to treat metastatic cancers. Our platform combines tissue-specific control of both viral replication and the expression of human cytokines to provide a dual punch in cancer cells.
A very interesting episode of BioTalk where Srujana Cherukuri, Ph.D. discusses her path from Intern to CEO and where the company is headed next
Before becoming CEO, Dr. Cherukuri served in multiple roles at Noble Life Sciences including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs. In her previous roles at Noble, Dr. Cherukuri was instrumental in optimizing new preclinical animal models and streamlining operations to achieve operational efficiency. In addition, Dr. Cherukuri led the successful consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri has expertise in diverse areas of Biology and has 12+ years of research experience in the areas of oncology and stem cell biology. Dr. Cherukuri completed her PhD in biology at Cleveland State University.
Listen now on iTunes, Google Play, and TuneIn.
AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China, that aims to nurture innovation by bringing together local and international companies, government, and medical and academic institutions to help create a world-class healthcare innovation ecosystem.
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo for trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate (ADC).
An ADC is a chemotherapy agent attached by a molecular linker to an antibody focused on a specific cancer marker. This way, the antibody delivers the toxic chemical directly to the tumors, minimizing the effects of the chemotherapy on healthy cells.
Pediatric orthopedic and spine medical device innovators –good news—the deadline has been extended until Tues., April 9 at midnight EST to apply for the NCC-PDI “Make Your Medical Device Pitch for Kids!” competition with $250K in awards.
This is your chance to capture up to $50,000 in funding and gain access to the first-ever NCC-PDI “Pediatric Device Innovator Accelerator Program” led by MedTech Innovator.
Innovators earning a spot at this one-of-a-kind pediatric accelerator will receive mentorship and support from NCC-PDI’s network of medtech executives, investors, specialty pediatricians and FDA regulatory and business consultants. All finalists will be offered pitch perfect coaching by Entrepreneurs-In-Residence at BioHealth Innovation.
The competition will be held April 30, 2019 at the University of Maryland, College Park. Be part of it!
Jump start your journey to commercialization. The first step is applying here before the April 9, 2019 midnight EST deadline.
Creatv MicroTech, detecting and diagnosing cancer when it matters most, will present its latest findings on cancer diagnosis and treatment at the Annual American Association for Cancer Research (AACR) Meeting at Atlanta, Georgia, March 29 – April 3, 2019. Two posters will showcase the clinical utility of cancer-associated macrophage-like cells (CAMLs) biomarker.
Abstract No. 437 / 9: “Combining circulating stromal cells with cell free DNA for increased sensitivity in profiling oncogenic mutations and indicates highly aggressive non-small-cell lung cancer,” investigating the clinical potential of Circulogene’s Patient Mutation Load (PML) analysis from matched cfDNA, CAMLs, and tumor tissue to evaluate progression free survival (PFS) and overall survival (OS) in non-small-cell lung cancer (NSCLC).
AstraZeneca has signed on to be a founding partner for a new life sciences research hub in China, to be housed just west of Shanghai.